Telix Pharmaceuticals Lim... (TLPPF)

PNK: TLPPF · Real-Time Price · USD

17.12

0.12 (0.70%)

At close: Apr 28, 2025, 1:24 PM

0.70% (1D)

Bid	17
Market Cap	5.78B
Revenue (ttm)	805.63M
Net Income (ttm)	28.61M
EPS (ttm)	0.09
PE Ratio (ttm)	190.22
Forward PE	n/a
Analyst	n/a

Ask	19.1
Volume	100
Avg. Volume (20D)	4,198
Open	17.12
Previous Close	17.00
Day's Range	17.12 - 17.12
52-Week Range	8.90 - 24.85
Beta	2.49

About TLPPF

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditi...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 25, 2019

Employees 415

Stock Exchange PNK

Ticker Symbol TLPPF

Website https://telixpharma.com

Full Company Profile

News

3 weeks ago · seekingalpha.com

Telix Pharmaceuticals: Building A Radiopharma Powerhouse

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term value through strategic investments and regulatory wins. Strong financial p...

2 months ago · reuters.com

Australia's Telix Pharmaceuticals scales record peak on upbeat revenue forecast

Shares of Telix Pharmaceuticals surged to a record high on Friday after the company forecast annual bumper revenue, while its full-year earnings for 2024 soared more than ninefold.

2 months ago · seekingalpha.com

Telix Pharmaceuticals Limited (TLPPF) FY 2024 Results Earnings Call Transcript

Telix Pharmaceuticals Limited (OTCPK:TLPPF) FY 2024 Results Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Kyahn Williamson – Senior Vice President-Investor Relations and C...